News
Management of Drug-Induced Diabetes Discussed in Review
The study authors focused on 4 pharmacologic classes: glucocorticoids, antiretroviral therapies, newer atypical antipsychotics, and immune checkpoint inhibitors.
Your search for olanzapine returned 8 results
News
Lybalvi Now Available for Schizophrenia, Bipolar I Disorder
Lybalvi is an atypical antipsychotic comprised of samidorphan co-formulated with olanzapine in a single bilayer tablet.
News
Lithium Compared With Newer Therapies as Adjunct to Antidepressants
The likelihood of help or harm, also known as the risk/benefit ratio, was found to be more favorable for lithium.
News
Lybalvi Approved for Schizophrenia, Bipolar I Disorder
The approval was based on data from 27 clinical studies, including the phase 3 ENLIGHTEN-1 and ENLIGHTEN-2 studies.
News
Medication Organizers Often Contain “One Pill Can Kill” Meds
While known to increase patient compliance, medication organizers, such as blister packs and pill boxes, have also been associated with unintentional pediatric medication exposures.
News
Review Examines Metabolic, Cardiovascular Side Effects of Second-Generation Antipsychotics
A systematic review examined the metabolic and cardiovascular adverse effects in commonly prescribed second-generation antipsychotics.
Drugs in the Pipeline
FDA Issues Complete Response Letter for Olanzapine/Samidorphan
While the CRL did not raise clinical concerns, the Agency noted that certain conditions related to the tablet coating process needed to be resolved.
Drugs in the Pipeline
FDA Committees Vote on Novel Therapy for Schizophrenia, Bipolar I Disorder
ALKS 3831 is composed of samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
